LifeSplice Pharma is an early-stage biotech company that develops extraordinarily specific, potent, and long lasting RNA-based drugs called ‘Splice Modulating Oligomers’ (SMOs) to treat severe neurological and non-neurological diseases with critical unmet medical needs. The LifeSplice platform technology relies upon innovative and cost-effective in-silico drug design, validated by its founding scientists, that allows for extremely rapid discovery of new SMO product candidates.